Proteon Therapeutics, Inc is a biopharmaceutical company developing pharmaceuticals to address the medical needs of patients with renal and vascular diseases. The company leverages a unique understanding of tissue remodeling to develop a pipeline of proprietary therapeutics. Proteon Therapeutics’ first drug candidate (PRT-201) is in development for the improvement of blood flow following vascular surgery procedures. The company’s initial clinical focus is vascular access for hemodialysis and peripheral arterial disease (PAD).

from http://www.proteontherapeutics.com/

Research Grants 2 show all


$158.2K
2004

$99.5K
2005

Patents 100show all

  • 30
    A61K - Preparations for medical, dental, or toilet purposes
  • 4
    A61M - Devices for introducing media into, or onto, the body

Clinical Trials 8show all

3Phase 12Phase 1/Phase 22Phase 31Phase 2

SEC Filings show all


59
8-K

16
10-Q

6
10-K

5
D

1
S-1

Contact Information

200 West Street
Waltham, MA 02451
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$145,538,66011-502014-05-16Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2014-02-19$4,338,660Series Unknown
2006-03-30$19,000,000Series APrism Venture Management, TVM CapitalSkyline Ventures, Intersouth Partners
2011-08-12$15,200,000Series CTVM CapitalIntersouth Partners, MPM Capital, Skyline Capital Partners, Prism Venture Management
2009-05-28$50,000,000Series BBessemer Venture Partners, Devon Park BioVenturesVectis Healthcare & Life Sciences Fund, TVM Capital, Intersouth Partners, Skyline Ventures, Prism Venture Management, MPM Bio IV NVS Strategic Fund
2007-09-06$12,000,000Series ADevon Park BioVentures, Bessemer Venture PartnersSkyline Ventures, TVM Capital, Intersouth Partners, Prism Venture Management
2014-05-16$45,000,000Series DAbingworthPrism Venture Management, Devon Park BioVentures, Bessemer Venture Partners, TVM Capital, Deerfield, Skyline Ventures, Pharmstandard, Inbio Ventures, MPM Capital, Intersouth Partners

SEC Form D Funding Events

DateOfferedSoldType
2014-05-28$29,565,934$29,565,934Equity
2014-02-19$4,338,660$4,338,660Equity, Debt, Option to Acquire
2011-08-11$15,183,371$15,183,371Equity, Option to Acquire
2009-03-11Unknown Unknown Other (Paper Filing)

Key Executives

  • Timothy Noyes
    Executive Officer, Director
  • F. Nicholas Franano
    Director
  • Brendan O'Leary
    Director
  • Gregory D. Phelps
    Director
  • David G. Lowe
    Director
  • Hubert Birner
    Director
  • Steven St. Peter
    Director
  • Dean Profis
    Executive Officer
  • Stephen Hoffman
    Director
  • Todd Foley
    Director
  • Tim Haines
    Director
  • Dmitry Kobyzev
    Director
  • John G. Freund
    Director
  • Steven K. Burke
    Executive Officer
  • Daniel P. Gottlieb
    Executive Officer
  • George Eldridge
    Executive Officer